Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Wu

Showing results (81-90 of 120) with videos related to

Pageof 12
Sort By:
Inflammatory Bowel Diseases|March 4, 2025
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical ProgramBruce E Sands, Marla C Dubinsky, Paulo G Kotze, et al.
RMD Open|June 2, 2022
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trialVictoria Navarro-Compán, James Cheng-Chung Wei, Filip Van den Bosch, et al.
JAMA Network Open|July 29, 2025
Psychological Well-Being in Clinical Research CoordinatorsRegina M Longley, M Tim Song, Daniel A Schaefer, et al.
Bioorganic & Medicinal Chemistry Letters|June 6, 2008
Discovery of new binding elements in DPP-4 inhibition and their applications in novel DPP-4 inhibitor designGui-Bai Liang, Xiaoxia Qian, Tesfaye Biftu, et al.
The American Journal of Gastroenterology|January 29, 2025
Body Mass Index Did Not Affect Efficacy and Safety of Etrasimod: A Post Hoc Analysis of the ELEVATE Ulcerative Colitis Clinical ProgramAndres J Yarur, Millie D Long, Joana Torres, et al.
Inflammatory Bowel Diseases|December 13, 2024
Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical ProgramAndres J Yarur, Michael V Chiorean, Jessica R Allegretti, et al.
Annals of the Rheumatic Diseases|January 4, 2023
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trialJeffrey R Curtis, Kunihiro Yamaoka, Yi-Hsing Chen, et al.
Nature Reviews. Physics|March 17, 2021
Modelling COVID-19Alessandro Vespignani, Huaiyu Tian, Christopher Dye, et al.
The Lancet. Rheumatology|January 27, 2024
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension studyPeter Nash, Laura C Coates, Dona Fleishaker, et al.
JACC. Advances|December 16, 2025
Clinical Characteristics Associated With Variability in Biopsy Grade Severity of Liver Fibrosis in Fontan CirculationTaylor Hartzel Houlihan, Ari Gartenberg, Kathryn M Dodds, et al.
Pageof 12

Showing results (81-90 of 120) with videos related to

Sort By:
Pageof 12
Inflammatory Bowel Diseases|March 4, 2025
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical ProgramBruce E Sands, Marla C Dubinsky, Paulo G Kotze, et al.
RMD Open|June 2, 2022
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trialVictoria Navarro-Compán, James Cheng-Chung Wei, Filip Van den Bosch, et al.
JAMA Network Open|July 29, 2025
Psychological Well-Being in Clinical Research CoordinatorsRegina M Longley, M Tim Song, Daniel A Schaefer, et al.
Bioorganic & Medicinal Chemistry Letters|June 6, 2008
Discovery of new binding elements in DPP-4 inhibition and their applications in novel DPP-4 inhibitor designGui-Bai Liang, Xiaoxia Qian, Tesfaye Biftu, et al.
The American Journal of Gastroenterology|January 29, 2025
Body Mass Index Did Not Affect Efficacy and Safety of Etrasimod: A Post Hoc Analysis of the ELEVATE Ulcerative Colitis Clinical ProgramAndres J Yarur, Millie D Long, Joana Torres, et al.
Inflammatory Bowel Diseases|December 13, 2024
Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical ProgramAndres J Yarur, Michael V Chiorean, Jessica R Allegretti, et al.
Annals of the Rheumatic Diseases|January 4, 2023
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trialJeffrey R Curtis, Kunihiro Yamaoka, Yi-Hsing Chen, et al.
Nature Reviews. Physics|March 17, 2021
Modelling COVID-19Alessandro Vespignani, Huaiyu Tian, Christopher Dye, et al.
The Lancet. Rheumatology|January 27, 2024
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension studyPeter Nash, Laura C Coates, Dona Fleishaker, et al.
JACC. Advances|December 16, 2025
Clinical Characteristics Associated With Variability in Biopsy Grade Severity of Liver Fibrosis in Fontan CirculationTaylor Hartzel Houlihan, Ari Gartenberg, Kathryn M Dodds, et al.
Pageof 12